Over the past year, PharmaBoardroom has spoken to pharma executives the world over, collecting unique perspectives from all sides of the industry.…

While patient groups view the United States' new Inflation Reduction Act as a positive move towards capping out-of-pocket drug costs for older…

The COVID-19 pandemic brought the issue of access to medicines to the forefront. Not only did supply chain disruptions lead to initiatives designed to…

Dan Leonard, President and CEO of the Association for Accessible Medicines (AAM) and Erik C. Komendant, the organisation's Senior Vice President of…

In the wake of Access! 2022, the Association for Accessible Medicines (AAM)’s first in-person annual summit in two years, AAM President and CEO Dan…

Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual…

Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his key agenda priorities as head of the…

The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure…

A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to…

AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value proposition of generic and…

As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…

AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the…